The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
June 7th 2024
Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Taking a Critical Look at Healthcare Inequity Among Patients with Cancer: What Role Do Onco-Nurses Play?
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
September 25th 2023The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
Holistic and Multidisciplinary Approaches to Multiple Myeloma Management
Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Impact of Clinical Trials on the Management of Multiple Myeloma
Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.
Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma
September 22nd 2023Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.
CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab mafodotin-blmf for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior treatments.
Importance of Clinical Trial Enrollment in Multiple Myeloma
Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.
Multiple Myeloma: Regulatory Aspects of Treatment Development and Approval
A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.
Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding a Type II variation application to extend the therapeutic indication of melphalan flufenamide for use in adult patients with multiple myeloma who have received at least 2 prior lines of treatment and whose disease is refractory to lenalidomide and the last line of therapy.
Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma
September 12th 2023Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.
FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma
The FDA has approved motixafortide (Aphexda) in combination with filgrastim (Neupogen) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplant in patients with multiple myeloma.
Educating Patients on Treatment Options for Multiple Myeloma
Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.
Treatment for Newly Diagnosed Multiple Myeloma: Addressing Disparities in Care
Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.
Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.
Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.
Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel
September 7th 2023Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.
Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma
Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.
Role of Diagnostic Testing in Patients with Multiple Myeloma
Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.
Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma
Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma.
Talquetamab Wins Approval in Europe for Relapsed/Refractory Myeloma
The European Commission has granted conditional marketing authorization to talquetamab-tgvs monotherapy for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies and have demonstrated disease progression on the last therapy.